1. Egler RA, Ahuja SP, et al. L-Asparaginase in the Treatment of Patients with Acute Lymphoblastic Leukemia. J Pharmacol Pharmacother. 2016;7(2):62-71. doi: 10.4103/0976-500X.184769.
2. Salzer, W., Bostrom, B., et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leukemia & Lymphoma. 2017. 59(8), 1797–1806. doi:10.1080/10428194.2017.1386305
3. Horvat, T. Z., Pecoraro, J. J., et al. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Leukemia Research. 2016. 50, 17–20. doi:10.1016/j.leukres.2016.08.014
4. Bobo, D., Robinson, K. J., et al. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharmaceutical Research. 2016. 33(10), 2373–2387. doi:10.1007/s11095-016-1958-5
5. Gupta S, Wang C, et al. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. J Clin Oncol. 2020 Jun 10;38(17):1897-1905. doi: 10.1200/JCO.19.03024.
6. Fung, MKL., Chan, GCF. Drug-induced amino acid deprivation as strategy for cancer therapy. Journal of Hematology & Oncology. 2017. 10(1). doi:10.1186/s13045-017-0509-9
7. Sullivan, L. B., Luengo, A., et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nature Cell Biology. 2018. 20(7), 782–788. doi:10.1038/s41556-018-0125-0
8. Liu, W., Wang, H., et al. Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitro. OncoTargets and Therapy. 2018. Volume 11, 6605–6615. doi:10.2147/ott.s155930
9. Lopes, A. M., Oliveira-Nascimento, L. et al. Therapeutic l-asparaginase: upstream, downstream and beyond. Critical Reviews in Biotechnology. 2015. 37(1), 82–99. doi:10.3109/07388551.2015.1120705
10. Baxalta Australia. Australian Public Assessment Report for pegaspargase. 2018. https://www.tga.gov.au/sites/default/files/auspar-pegaspargase-180918.pdf.
11. Lomelino, C.L., Andring, J.T., et al. Asparagine synthetase: Function, structure, and role in disease. Journal of Biological Chemistry. 2017. 292(49), 19952–19958. doi:10.1074/jbc.r117.819060
12. Rau, R.E., Dreyer, Z., et al. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children’s Oncology Group. Pediatric Blood & Cancer. 2017. 65(3), e26873. doi:10.1002/pbc.26873
13. Gerson, S.L., Caimi, P F., et al. Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies. Hematology. 2018. 849–912. doi:10.1016/b978-0-323-35762-3.00057-3
14. Pegaspargase (Rx). Medscape. 2023. https://reference.medscape.com/drug/oncaspar-peg-l-asparaginase-pegaspargase-342225#10